SCHEMBL5569616

SCHEMBL5569616

CC(C)(C)OC(=O)N1CCC(CC(CC2CCN(C(=O)OC(C)(C)C)CC2)NC(=O)OCc2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
YAP1 P46937 3/20 0.55
KDM4E B2RXH2 1/20 0.53
PKM P14618 1/20 0.53
SYK P43405 1/20 0.53
STS P08842 1/20 0.51
GPR119 Q8TDV5 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
BACE1 P56817 1/20 0.50
P2RX7 Q99572 6/20 0.49
HTT P42858 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
NTSR1 P30989 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18788023 0.90 YAP1 (0.60) YAP1KDM4EPKMSTSGPR119
SCHEMBL20556236 0.90 YAP1 (0.60) YAP1KDM4EPKMSTSGPR119
SCHEMBL12249924 0.89 YAP1 (0.62) YAP1KDM4EPKMSTSGPR119
SCHEMBL18822510 0.89 YAP1 (0.62) YAP1KDM4EPKMSTSGPR119
SCHEMBL12249929 0.88 YAP1 (0.56) YAP1KDM4EPKMSTSGPR119
SCHEMBL5331489 0.88 SYK (0.58) YAP1KDM4EPKMSYKSTS
SCHEMBL3008274 0.86 YAP1 (0.60) YAP1KDM4EPKMP2RX7MAPT
SCHEMBL12652625 0.86 YAP1 (0.60) YAP1KDM4EPKMP2RX7MAPT
SCHEMBL3008280 0.86 YAP1 (0.60) YAP1KDM4EPKMP2RX7MAPT
SCHEMBL2999886 0.85 YAP1 (0.62) YAP1KDM4EPKMP2RX7HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1057815-B1 CYCLIC AMIDE COMPOUNDS KOWA CO (JP) 2007-09-05 EP disclosed
US-6645957-B2 Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis KOWA CO., LTD. (JP) 2003-11-11 US disclosed
US-20030096828-A1 Cyclic amide compound KOWA CO., LTD. (JP) 2003-05-22 US disclosed
US-6448242-B1 COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS KOWA CO., LTD. (JP) 2002-09-10 US disclosed
EP-1057815-A1 CYCLIC AMIDE COMPOUNDS Kowa Co., Ltd. (JP) 2000-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096828-A1 Cyclic amide compound CMA1, HRH2, HRH4 YAP1 3899/4885KDM4E 218/4885PKM 4761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.